drugset
drugset / Trial / NCT05246878

A Study of EDP-235 in Healthy Subjects

NCT05246878 ↗

Phase 1 Completed 72 enrolled Enanta Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.

Timeline

Start
2022-01-28
Primary completion
2022-07-20
Completion
2022-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP-235 Unknown — Oral

Indications

COVID-19